Summary
Based on the important role of CD44 in tumour progression and metastasis, we evaluated, in a prospective study, plasma-soluble CD44 (sCD44) as a serum marker in colorectal cancer. Blood plasma specimens from 89 patients with colorectal neoplasm, 22 patients with a gastrointestinal disease and 23 healthy donors were analysed for quantitation (ELISA assay) and purification of sCD44. The concentration of sCD44, indicating the concentration of all isoforms, was significantly higher in patients with colorectal cancer and intestinal disease than in normal individuals, but no significant differences were found between the two groups. We found no association between plasma levels and staging of the colorectal cancer patients according to Astler and Coller. A two-step batch purification combining ion exchange and immunoaffinity chromatography, followed by Western blot analysis, revealed a complex pattern with a major band corresponding to the standard form of CD44 and minor bands that may correspond to larger variant forms. No particular sCD44 isoform was clearly associated with anatomopathological or biological information.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Arch, R., Wirth, K., Hofmann, M., Ponta, H., Matzku, S., Herrlich, P. & Zöller, M. (1992). Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science 257: 682–685.
Astler, V. B. & Coller, F. A. (1954). The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 139: 846–851.
Aruffo, A., Stamenkovic, I., Melnick, M., Underhill, C. B. & Seed, B. (1990). CD44 is the principal cell surface receptor for hyaluronate. Cell 61: 1303–1313.
Bazil, V. & Strominger, J. L. (1994). Metalloprotease and serine protease are involved in cleavage of CD43, CD44, and CD16 from stimulated human granulocytes. J Immunol 152: 1314–1322.
Blanchard, D., Petit-LeRoux, Y., Willem, C. & Loirat, M. J. (1997). Flow cytometry and immunoblotting analysis of monoclonal antibodies directed to CD-related antigens. Transfus Clin Biol 4: 153–156.
Combaret, V., Gross, N., Lasset, C., Frappaz, D., Peruisseau, G., Philip, T., Beck, D. & Favrot, M. C. (1996). Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. J Clin Oncol 14: 25–34.
De Rossi, G., Marroni, P., Paganuzzi, M., Mauro, F. R., Tenca, C., Zarcone, D., Velardi, A., Molica, A. & Grossi, C. E. (1997). Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell lymphocytic leukemia. Leukemia 11: 134–141.
Galmiche, A. & Lustenberger, P. (1994). CD44, invasion tumorale et métastase. Med Sci 10: 1282–1291.
Gorham, H., Sugino, T., Woodman, A. C. & Tarin, D. (1996). Cellular distribution of CD44 gene transcripts in colorectal carcinomas and in normal colonic mucosa. J Clin Pathol 49: 482–488.
Gotley, D. C., Fawcett, J., Walsh, M. D., Reeder, J. A., Simmons, D. L. & Antalis, T. M. (1996). Alternatively spliced variants of the cell adhesion molecule CD44 and tumour progression in colorectal cancer. Br J Cancer 74: 342–351.
Günthert, U., Hofmann, M., Rudy, W., Reber, S., Zöller, M., Haußmann, I., Matzku, S., Wenzel, A., Ponta, H. & Herrlich, P. (1991). A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65: 13–24.
Guo, Y. J., Liu, G., Wang, X., Jin, D., Wu, M., Ma, J. & Sy, M. S. (1994). Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res 54: 422–426.
Harn, H. J., Ho, L. I., Shyu, R. Y., Yuan, J. S., Lin, F. G., Young, T. H., Liu, C. A., Tang, H. S. & Lee, W. H. (1996). Soluble CD44 isoforms in serum as potential markers of metastatic gastric carcinoma. J Clin Gastroenterol 22: 107–110.
Higashikawa, K., Yokozaki, H., Ue, T., Taniyama, K., Ishikawa, T., Tarin, D. & Tahara, E. (1996). Evaluation of CD44 transcription variants in human digestive tract carcinomas and normal tissues. Int J Cancer 66: 11–17.
Huet, S., Groux, H., Caillou, B., Valentin, H., Prieur, A. M. & Bernard, A. (1989). CD44 contributes to T cell activation. J Immunol 143: 798–801.
Imazeki, F., Yokosuka, O., Yamaguchi, T., Ohto, M., Isono, K. & Omata, M. (1996). Expression of variant CD44-messenger RNA in colorectal adenocarcinomas and adenomatous polyps in humans. Gastroenterology 110: 362–368.
Kan, M., Kanayama, H. O., Naruo, S., Tsuji, M., Kojima, K., Kurokawa, Y. & Kagawa, S. (1996). Serological evaluation of soluble CD44 in renal cancer. Jpn J Cancer Res 87: 1191–1194.
Katoh, S., McCarthy, J. B. & Kincade, P. W. (1994). Characterization of soluble CD44 in the circulation of mice. J Immunol 153: 3440–3449.
Labarriere, N., Piau, J. P., Otry, C., Denis, M., Lustenberger, P., Meflah, K. & Le Pendu, J. (1994). Level of H-blood group expression in CD44v modulates lak cell lysis sensitivity and tumorigenicity of rat colon carcinoma cells. Cancer Res 54: 6275–6281.
Lein, M., Weiß, S., Jung, K., Schnorr, D. & Loening, S. (1996). Soluble CD44 variants in serum of patients with prostate cancer and other urological malignancies. Prostate 29: 334–335.
Lucas, M. G., Green, A. M. & Telen, M. J. (1989). Characterization of serum In (Lu)-related antigen: identification of a serum protein related to erythrocyte p80. Blood 73: 596–600.
Martin, S., Jansen, F., Bokelmann, J. & Kolb, H. (1997). Soluble CD44 splice variants in metastasizing human breast cancer. Int J Cancer (Pred Oncol) 74: 443–445.
Rafi, A., Nagarkatti, M. & Nagarkatti, P. S. (1997). Hyaluronate-CD44 interactions can induce murine B-cell activation. Blood 89: 2901–2908.
Ristamäki, R., Joensuu, H., Hagberg, H., Kalkner, K. M. & Jalkanen, S. (1998). Clinical significance of circulating CD44 in non-Hodgkin’s lymphoma. Int J Cancer (Pred Oncol.) 79: 221–225.
Ristamäki, R., Joensuu, H., Grön-Virta, K., Salmi, M. & Jalkanen, S. (1997). Origin and function of circulating CD44 in non-Hodgkin’s lymphoma. J Immunol 158: 3000–3008.
Screaton, G. R., Bell, M. V., Jackson, D. G., Cornelis, F. B., Geth, U. & Bell, J. I. (1992). Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 89: 12160–12164.
Sliutz, G., Tempfer, C., Winkler, S., Kohlberger, P., Reinthaller, A. & Kainz, C. (1995). Immunohistochemical and serological evaluation of CD44 splice variants in human ovarian cancer. Br J Cancer 72: 1494–1497.
Weg-Remers, S., Hildebrandt, U., Feifel, G., Moser, C., Zeitz, M. & Stallmach, A. (1998). Soluble CD44 and Cd44v6 serum levels in patients with colorectal cancer are independent of tumor stage and tissue expression of CD44v6. Am J Gastroenterol 93: 790–794.
Yu, Q. & Toole, B. P. (1996). A new alternatively spliced exon between v9 and v10 provides a molecular basis for synthesis of soluble CD44. J Biol Chem 271: 20603–20607.
Zeimer, A. G., Widschwendter, M., Uhl-Steidl, M., Muller-Holzner, E., Daxenbichler, G., Marth, C. & Dapunt, O. (1997). High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer. Br J Cancer 76: 1646–1651.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Masson, D., Denis, M., Denis, M. et al. Soluble CD44: quantification and molecular repartition in plasma of patients with colorectal cancer. Br J Cancer 80, 1995–2000 (1999). https://doi.org/10.1038/sj.bjc.6690633
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690633
Keywords
This article is cited by
-
Label-free fiber-optic spherical tip biosensor to enable picomolar-level detection of CD44 protein
Scientific Reports (2021)
-
Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications
Leukemia (2014)
-
Impact of ERβ and CD44 expression on the prognosis of patients with stage II colon cancer
Tumor Biology (2012)
-
Serum CD44 levels and overall survival in patients with HER2-positive breast cancer
Breast Cancer Research and Treatment (2011)
-
Evaluation of CD44 and CD44v6 in Colorectal Carcinoma Patients: Soluble Forms in Relation to Tumor Tissue Expression and Metastasis
Journal of Gastrointestinal Cancer (2008)